Challenging allograft use for aortic valve infective endocarditis: Is it the allograft or the surgeon?  Syed T. Hussain, MD, Eugene H. Blackstone, MD,

Slides:



Advertisements
Similar presentations
Operative outcomes in mitral valve surgery: Combined effect of surgeon and hospital volume in a population-based analysis  Arman Kilic, MD, Ashish S.
Advertisements

Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.
Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 
Of mice and men and surgical transcatheter aortic valve insertion
Stapled excision of the left atrial appendage
Residual patient, anatomic, and surgical obstacles in treating active left-sided infective endocarditis  Syed T. Hussain, MD, Nabin K. Shrestha, MD, Steven.
Challenging homografts as the holy grail for aortic valve endocarditis
Lars G. Svensson, MD, PhD, Eugene H. Blackstone, MD 
A comprehensive review of the PARTNER trial
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Lars G. Svensson, MD, PhD, Lillian H. Batizy, MS, Eugene H
Endovascular versus open elephant trunk completion for extensive aortic disease  Eric E. Roselli, MD, Sreekumar Subramanian, MD, Zhiyuan Sun, BS, Jahanzaib.
Surgical treatment of pseudoaneurysm of the thoracic aorta
Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society.
Centers for Disease Control “increased-risk” organ donor: Not so risky?  Francis D. Pagani, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery 
Victor van Berkel, MD, PhD 
Multilevel data analysis: What? Why? How?
Should lung transplantation be performed using donation after cardiac death? The United States experience  David P. Mason, MD, Lucy Thuita, MS, Joan M.
Bicuspid aortic valve aortopathy: One size fits all?
Mechanical valves versus the Ross procedure for aortic valve replacement in children: Propensity-adjusted comparison of long-term outcomes  Bahaaldin.
A. Marc Gillinov, MD, Eugene H. Blackstone, MD, Edward R
Capturing echocardiographic allograft valve function over time after allograft aortic valve or root replacement  M. Mostafa Mokhles, PhD, MSc, Jeevanantham.
Bigger The Journal of Thoracic and Cardiovascular Surgery
Use of annulus washer after debridement: A new mitral valve replacement technique for patients with severe mitral annular calcification  Syed Tarique.
Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement  Ole Lund, MD, PhD, Martin Bland,
The lord of the rings  Antonio Miceli, MD, PhD 
A. Marc Gillinov, MD, Patrick M. McCarthy, MD, Eugene H
The variability of the mitral valve anatomy and terminology
Support Your Specialty
Transcatheter aortic valve replacement in intermediate-risk patients
Innovation and science: The future of valve design
The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery  Vinay Badhwar, MD  The Journal of Thoracic and.
Michele Gallo, MD, Gino Gerosa, MD 
Military surgeons just want to have fun
Are allografts the biologic valve of choice for aortic valve replacement in nonelderly patients? Comparison of explantation for structural valve deterioration.
Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies  J. James Edelman, MBBS(Hons), PhD, Vinod H. Thourani,
Bahaaldin Alsoufi, MD, Cedric Manlhiot, BSc, Brian W
Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005  Scott D. Barnett, PhD,
The Journal of Thoracic and Cardiovascular Surgery
Tirone E. David, MD, Gheorghe Gavra, MD, Christopher M
J. Jay Idrees, MD, Eric E. Roselli, MD, Amr Arafat, MD, Douglas R
Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD 
The diabetes epidemic and its effect on cardiac surgery practice
Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD 
Replicating the success of mitral valve repair in the aortic valve
Frank C. Spencer, MD, FACS, pioneering cardiothoracic surgeon
Commentary: Do the right thing! Ethical versus legal
Passing the torch The Journal of Thoracic and Cardiovascular Surgery
Hans-Joachim Schäfers, MD 
Concomitant replacement of the ascending aorta is free—for some
In pregnancy, aortic tissue is the issue
Arvind K. Agnihotri, MD (by invitation), David C
The Journal of Thoracic and Cardiovascular Surgery
Discussion The Journal of Thoracic and Cardiovascular Surgery
Pulmonary hypertension is associated with worse early and late outcomes after aortic valve replacement: Implications for transcatheter aortic valve replacement 
Tissue valve, nitinol stent, or storage solution
A. Marc Gillinov, MD, Jon Sirak, MD, Eugene H
Permanent pacemaker insertion following transcatheter aortic valve replacement: Not infrequent, not benign, and becoming predictable  Craig M. Jarrett,
Commentary: When a choice is not an echo
Aortic root surgery for young patients: The elephant in the room
Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement  Todd M. Dewey,
Raja M. Flores, MD  The Journal of Thoracic and Cardiovascular Surgery 
Vinay Badhwar, MD, John S. Ikonomidis, MD, PhD, Jeffrey P. Jacobs, MD 
“The more things change…”: The challenges ahead
Toward a more rational approach in treating type B aortic dissection
Racing to the Rubicon  Michael J. Reardon, MD, Vinod H. Thourani, MD 
Identifying risk factors: Challenges of separating signal from noise
Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement?  F. Dagenais, MD, P. Cartier, MD, P. Voisine,
Journal changes and initiatives
Paul Philipp Heinisch, MD, Thierry Carrel, MD 
Presentation transcript:

Challenging allograft use for aortic valve infective endocarditis: Is it the allograft or the surgeon?  Syed T. Hussain, MD, Eugene H. Blackstone, MD, Gösta B. Pettersson, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 153, Issue 2, Pages 280-281 (February 2017) DOI: 10.1016/j.jtcvs.2016.09.005 Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Hazard function for recurrent endocarditis in patients who underwent aortic valve replacement for infective endocarditis at an Australian center, stratified by mechanical prostheses and xenografts versus allografts. Early risk peaks within 6 weeks for the mechanical and xenograft group, compared with a low, constant risk in the allograft group. Dashed lines enclose 70% confidence limits. (Modified with permission from: McGiffin DC, Galbraith AJ, McLachlan GJ, Stower RE, Wong ML, Stafford EG, et al. Aortic valve infection. Risk factors for death and recurrent endocarditis after aortic valve replacement. J Thorac Cardiovasc Surg. 1992;104:511-20. Copyright Elsevier 1992.) In contrast, patients who were treated for aortic prosthetic valve infective endocarditis with surgical debridement of infected tissue and aortic root replacement with a commercial cryopreserved aortic allograft at an American center had a late-peaking risk at approximately 9 months (inset). Dashed lines enclose 68% confidence limits. (Modified with permission from: Sabik JF, Lytle BW, Blackstone EH, Marullo AG, Pettersson GB, Cosgrove DM. Aortic root replacement with cryopreserved allograft for prosthetic valve endocarditis. Ann Thorac Surg. 2002;74:650-9; discussion 9. Copyright Elsevier 2002.) The Journal of Thoracic and Cardiovascular Surgery 2017 153, 280-281DOI: (10.1016/j.jtcvs.2016.09.005) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

The Journal of Thoracic and Cardiovascular Surgery 2017 153, 280-281DOI: (10.1016/j.jtcvs.2016.09.005) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions